Benitec Biopharma Inc. (BNTC) Income Statement
BNTC FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsBNTC revenue and net income
BNTC growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BNTC quarterly EPS vs estimates
Benitec Biopharma beat the analyst EPS estimate in 5 of the last 7 quarters. Next report: November 13, 2026 (estimate $-0.28).
BNTC income statement
| FY2026 | FY2025 | |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of revenue | $481,000 | $396,000 |
| Gross profit | −$481,000 | −$396,000 |
| Research & development | $23.4M | $18.3M |
| Sales, general & admin | $27.8M | $23.4M |
| Total operating expenses | $50.7M | $41.4M |
| Operating income | −$51.2M | −$41.8M |
| Interest expense | — | $3.3M |
| Income before taxes | −$45.5M | −$37.9M |
| Net income | −$45.5M | −$37.9M |
| EBITDA | −$50.7M | −$41.4M |
| EPS (diluted) | −$0.98 | −$1.47 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $556,000 | $0 | $0 |
| Cost of revenue | $124,000 | $119,000 | $120,000 | $118,000 | $278,000 | $106,000 | $81,000 |
| Gross profit | −$124,000 | −$119,000 | −$120,000 | −$118,000 | $278,000 | −$106,000 | −$81,000 |
| Research & development | $9.6M | $6.3M | $5.8M | $3.4M | $3.7M | $6.5M | $5.4M |
| Sales, general & admin | $6.5M | $7.3M | $7.5M | $6.4M | $13.5M | $8.8M | $5.4M |
| Total operating expenses | $14.3M | $13.5M | $13.3M | $9.6M | $9.7M | $15.2M | $10.7M |
| Operating income | −$14.4M | −$13.6M | −$13.4M | −$9.8M | −$9.8M | −$15.3M | −$10.8M |
| Interest income | — | $1.6M | — | — | — | $823,000 | $823,000 |
| Interest expense | $1.0M | — | $1.4M | $1.0M | $1.0M | $823,000 | $823,000 |
| Income before taxes | −$12.8M | −$11.9M | −$11.8M | −$9.0M | −$8.8M | −$14.5M | −$9.6M |
| Income taxes | — | — | — | — | — | — | −$7.4M |
| Net income | −$12.8M | −$11.9M | −$11.8M | −$9.0M | −$16.1M | −$14.5M | −$9.6M |
| EBITDA | −$14.3M | −$13.5M | −$13.3M | −$9.7M | −$17.1M | −$15.2M | −$10.7M |
| EPS (diluted) | −$0.26 | −$0.24 | −$0.26 | −$0.22 | −$0.42 | −$0.24 | −$0.33 |
| Gross margin | — | — | — | — | 50.0% | — | — |
| Operating margin | — | — | — | — | −1,768.7% | — | — |
| Net margin | — | — | — | — | −2,904.1% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BNTC's financial statements (latest annual report filed September 14, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BNTC financial results
Benitec Biopharma reported no revenue in fiscal year 2026 (ended June 30, 2026). It had a net loss of $45.5 million. Diluted earnings per share came to −$0.98.
See the BNTC stock overview for the latest quote and news, or the BNTC chart for price history and technical indicators.
BNTC income statement FAQ
Does Benitec Biopharma have revenue?
Benitec Biopharma reported no revenue for fiscal year 2026, which ended on June 30, 2026.
Is Benitec Biopharma profitable?
No. Benitec Biopharma reported a net loss of $45.5 million in fiscal 2026.
How much does Benitec Biopharma spend on research and development?
Benitec Biopharma spent $23.4 million on research and development in fiscal 2026.
What are Benitec Biopharma's earnings per share?
Benitec Biopharma earned $-0.98 per diluted share in fiscal 2026, compared with $-1.47 a year earlier.
When will Benitec Biopharma report its next earnings?
Benitec Biopharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Benitec Biopharma's fiscal year end?
Benitec Biopharma's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on September 14, 2026.